Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD5335 + Itraconazole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD5335 | AZD 5335|AZD-5335 | FOLR1-targeted Therapy 24 | AZD5335 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) linked to a topoisomerase 1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (8_Supplement): LB025). | |
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07402915 | Phase I | AZD5335 + Itraconazole | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Recruiting | IRL | ESP | 2 |